Kaia COPD vs Mechanical Ventilation Expert

We support you in everyday life with a digital therapy program that you can use anytime, anywhere without stressful journeys or waiting time. Learn: - Breathing techniques to better cope with shortness of breath - Movement exercises that improve your performance - Tips and in-depth information on living a more active life with COPD Kaia COPD offers you an individual therapy program that is tailored to your needs. Every day you will receive a mix of exercises including knowledge units, relaxation and movement. All content was developed in collaboration with lung specialists in order to offer you effective methods of pulmonary rehabilitation at home. If you have any questions, you can always contact our team: Phone: +49 89 904 226 740 (Monday to Friday 9:30 a.m. - 5:00 p.m.) E-Mail: support@kaiahealth.de Why is Kaia COPD so effective? - The training is adapted to your fitness level. You also determine the difficulty of the exercises yourself. - With our movement coach, a digital trainer, the app ensures that you perform the exercises correctly. The movement coach analyzes your posture via the camera of your smartphone or tablet and gives you feedback in real time. - A clinical study has shown that users of Kaia COPD can increase their physical resilience and performance. The therapy also showed to have a positive impact on health-related quality of life. Medical purpose: Kaia COPD is a medical product based on the concept of pulmonary rehabilitation for use by people with COPD. Each time the app is used, Kaia delivers new course units to promote physical activity and to help people proactively manage their COPD. Kaia COPD supports people aged 18 years or older with a diagnosis of COPD (J44.-) as long as contraindications and other causes for symptoms which require specific therapy are excluded. Kaia COPD cannot diagnose conditions or injuries and cannot replace a medical consultation. Contraindications: Advanced heart failure (I50.-), heart disease, other unexplained cardiovascular system disorders (I51.-) Pulmonary embolism, pulmonary artery infarction (I26.-) or deep vein thrombosis (I80.2-) Current infection/exacerbation with worsening dyspnea (J44.1-) pregnancy (O09.-) Additional Information: Instructions for use and relative contraindications: https://www.kaiahealth.de/rechtliches/gebrauchsanweisung-fuer-copd Privacy policy: https://www.kaiahealth.de/rechtliches/datenschutzerklaerung-apps/ Terms and conditions: https://www.kaiahealth.de/rechtliches/agb/ Kaia COPD uses Apple HealthKit for accessing step tracker data on your device. This is an optional function. The step tracker data is used only after the user activates the function.

Caution! This app is intended for intensive care physicians. If you are NOT a physician and would like to use it anyway, please consult your physician before using this app or making any medical decisions. This app has endorsement for usage in the Russian Federation. Many doctors deal with the treatment of patients with varying degrees of acute respiratory failure (ARF). But the choice of the optimal method and, especially, the timely correction of the parameters of invasive and non-invasive mechanical lung ventilation often cause difficulties, especially for young doctors. Unfortunately, expensive ventilation machines, without their skillful use, are not a guarantee of an improvement in the mortality rate in ARF. This has been especially evident during the COVID-19 pandemic. In international clinical practice, it is customary to determine the degree of ARF by the oxygenation index (the ratio of the partial pressure of oxygen in arterial blood (PaO2) to the fraction of inspired oxygen (FiO2)). This indicator is also included in most "severity of illness" scoring systems (SOFA, APACHE II-III, etc.). However PaO2 estimation is only possible after collecting the arterial blood for laboratory monitoring of blood gases, making it costly and invasive. In 2020-2021 a multicenter research was carried out at five clinical hospitals in Volgograd, Russia, which included 1038 patients with acute lung injury and acute respiratory distress syndrome against the background of viral (COVID-19) and bacterial pneumonia. The goals of the research were firstly, to develop a non-invasive method for determining the oxygenation index (PaO2 / FiO2) based on oxygen saturation (SpO2), and secondly, to define general criteria for correcting the parameters of invasive and non-invasive mechanical ventilation. This application is based on the results of the research. The relationship between SpO2 and PaO2 index values was determined for various FiO2 and types of respiratory support. The app also implements the general principle of oxygen therapy - from less to more invasive. The app allows the user not only to choose the most effective method of respiratory support, but also timely learn about the need for its correction. Every clinician knows that the mortality rate in patients with ARF is greatly influenced by the validity of the beginning and end of Invasive Mechanical Ventilation treatment - and this app solves this problem. The educational effect of this app should also be noted. It will help doctors to quickly master and more competently use expensive ventilation machines, which, of course, will have a beneficial effect on the results of treatment of patients with ARF. The following sources were used to create the app: 1. Brown SM, Grissom CK, Moss M, Rice TW, Schoenfeld D, Hou PC, Thompson BT, Brower RG; NIH/NHLBI PETAL Network Collaborators. Nonlinear Imputation of Pao2/Fio2 From Spo2/Fio2 Among Patients With Acute Respiratory Distress Syndrome. Chest. 2016 Aug;150(2):307-13. doi: 10.1016/j.chest.2016.01.003. Epub 2016 Jan 19. PMID: 26836924; PMCID: PMC4980543. 2. Bilan N, Dastranji A, Ghalehgolab Behbahani A. Comparison of the spo2/fio2 ratio and the pao2/fio2 ratio in patients with acute lung injury or acute respiratory distress syndrome. J Cardiovasc Thorac Res. 2015;7(1):28-31. doi: 10.15171/jcvtr.2014.06. Epub 2015 Mar 29. PMID: 25859313; PMCID: PMC4378672. 3. Yoshida T, Takegawa R, Ogura H. [Ventilatory strategy for ARDS]. Nihon Rinsho. 2016 Feb;74(2):279-84. Japanese. PMID: 26915253. 4. Fan E, Brodie D, Slutsky AS. Acute Respiratory Distress Syndrome: Advances in Diagnosis and Treatment. JAMA. 2018 Feb 20;319(7):698-710. doi: 10.1001/jama.2017.21907. PMID: 29466596. 5. Петров, В. И. Эволюция клинико-фармакологических и терапевтических принципов лечения инфекции COVID-19 / Петров В. И. [и др. ]. - Москва : ГЭОТАР-Медиа, 2021. - 312 с. - DOI: 10.33029/9704-6386-4-ECPC-2021-1-312. - ISBN 978-5-9704-6386-4.